Human papillomavirus vaccine - MediGene/Virionics

Drug Profile

Human papillomavirus vaccine - MediGene/Virionics

Alternative Names: CVLP tumour vaccine - MediGene/Virionics; HPV-16 L1-E7 chimeric VLP - MediGene/Virionics; Human papillomavirus type 16 L1-E7 chimeric virus-like particle vaccine - MediGene/Virionics; PapViRx

Latest Information Update: 30 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MediGene AG
  • Developer MediGene AG; Virionics
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Anal intraepithelial neoplasia; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections; Vulvar intraepithelial neoplasia

Most Recent Events

  • 11 Mar 2008 Preclinical trials in Cervical intraepithelial neoplasia in USA (unspecified route)
  • 11 Mar 2008 Preclinical trials in Human papillomavirus infections in USA (unspecified route)
  • 04 Apr 2006 Human papillomavirus vaccine licensed to Virionics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top